Brief: Fusion Antibodies Initiates Restructuring, Slashing Costs by 38% Including Headcount Reduction
30/04/2024 08:14
April 30 (Reuters) - Fusion Antibodies PLC FAB.L :
* YEAR-END TRADING STATEMENT
* TOOK STEPS TO MEET CHALLENGES IN H1 THROUGH RESTRUCTURING
EXERCISE, REDUCING VARIOUS COSTS INCLUDING 38% REDUCTION IN
HEADCOUNT
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Fusion Antibodies
See all newsBrief: Fusion Antibodies Announces New TGE And Cryoem Project With US Pharma Client
Fusion Antibodies - Contract win
Fusion Antibodies - AGM statement H1 trading and research update
RCS - Fusion Antibodies - Launch of new customer-focused website
Fusion Antibodies - Posting of Annual Report & Notice of AGM